• Abbvie Inc., of Chicago, shared results of a posthoc analysis of a Phase II study of Humira (adalimumab) for patients with hidradenitis suppurativa. The analysis showed that Humira produced a significant response rate in patients with moderate to severe disease at 16 weeks compared to placebo for the two dosing regimens assessed.